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Abstract. Background/Aim: Esophageal squamous cell carcinoma (ESCC) is one of 
the most difficult malignancies to cure. C4d is a degradation product of the classical 
complement pathway and is suggested as an early diagnostic marker for other 
SCCs. The purpose of this study was to clarify the association of complement C4d 
with ESCC. Patients and Methods: Immunohistochemical staining for C4d was 
performed on surgical specimens obtained from 114 patients with ESCC. 
Results: Positive C4d expression was observed in 70 (61.4%) cases and negative 
expression in 44 (38.6%) cases. There was a significant inverse correlation between 
C4d expression and depth of tumor invasion (p=0.0001), lymph node metastasis 
(p=0.011), lymphatic invasion (p=0.033), and TNM stage (p=0.0021). Kaplan–Meier 
analysis showed that negative C4d expression tended to lead to shorter overall 
survival (p=0.232). Conclusion: C4d expression in ESCC might be useful in 
developing treatment strategies or suppression of ESCC.  
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Esophageal squamous cell carcinoma (ESCC) is the major histological type of 
esophageal cancer in East Asian countries (1) and the eighth most common form of 
cancer worldwide (2). It is one of the most difficult malignancies to cure. It has a poor 
prognosis compared with other types of digestive cancer because of its high 
frequency of lymph node metastasis and recurrence (3). The overall 5-year survival 
rate of patients with ESCC is <20% (4), therefore early diagnosis is one of the most 
important factors for patient survival.  
 
  Two hypotheses are proposed for the role of the immune system in cancer 
initiation and progression. Firstly, the traditional hypothesis is that long-term 
inflammatory reactions promote cancer progression. Secondly, the cancer 
immunoediting theory postulates that the immune system protects the host against 
cancer development (5-11). Complement is a central component of innate immunity 
and plays an essential role in immune surveillance and homeostasis (12). The 
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complement system is an essential part of the inflammatory response and innate 
immunity to infection (13). 
In various tumor types, complement activation, particularly of the classical 
pathway, is reported to be related to carcinogenesis (14-16). C4d is a degradation 
(activation) product of the classical complement pathway. It is suggested that C4d is 
a useful early diagnostic marker in lung cancer or oropharyngeal SCC and related to 
their prognosis (17, 18). 
The purposes of the present study were to analyze the clinical significance of 
C4d in ESCC by immunohistochemistry, and to examine the relationship between 
C4d expression and clinicopathological parameters and patient survival. 
 
Patients and Methods  
Patient characteristics. Between May 2009 and March 2015, 199 patients with ESCC 
underwent transthoracic esophagectomy by the McKeown technique at the Dokkyo 
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Medical University Hospital, Japan. Surgical tissue samples were obtained from 114 
patients, which excluded 69 patients who had received neoadjuvant therapy and 16 
who underwent salvage surgery. There were 97 male (85.1%) and 17 female 
(14.9%) patients, with a mean age of 69 years (range=40-86 years). Tumor stage 
and disease grade were classified according to the seventh edition of the TNM 
classification of the International Union Against Cancer (UICC) (19). All patients 
signed informed consent forms according to our institutional guidelines. 
 
Immunohistochemistry. Resected specimens were fixed with 10% neutral-buffered 
formalin and embedded in paraffin blocks. Four-micrometer-thick sections were 
deparaffinized with xylene, hydrated through a series of graded alcohol solutions, 
and immersed in 3% hydrogen peroxide in absolute methanol for 30 min. The 
sections were washed with distilled water and phosphate-buffered saline (PBS; pH 
6.0). Antigens were retrieved by immersion in preheated 0.01 M citrate buffer (pH 
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6.0) and heating in an autoclave at 120°C for 20 min. The sections were incubated 
with rabbit anti-C4d polyclonal antibody (1: 50 dilution; Biomedica, Vienna, Austria) 
at room temperature for 1 h in a high-humidity chamber. After washing in PBS, the 
sections were incubated with biotinylated anti-rabbit IgG for 30 min at room 
temperature, followed by incubation with an avidin–biotin–peroxidase complex 
solution (VECTASTAIN® ABC Kit; Vector Laboratories, Burlingame, CA, USA). 
Peroxidase activity was visualized by incubation in 0.02% 3,3’-diaminobenzidine 
tetrahydrochloride with hematoxylin, dehydrated, and mounted in aqueous medium. 
C4d staining was evaluated by two pathologists blinded to the clinicopathological 
background of the patients. Normal epithelial tissue, present on each slide, was used 
as internal control. Negative C4d expression was defined as identical or weaker 
staining than in the internal control, and positive C4d expression was defined as 
stronger staining than in the internal control.  
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Statistical analysis. Statistical analysis was performed by χ2 and t-tests. Survival 
parameters were determined using the Kaplan–Meier method and compared using 
the log-rank test. Univariate and multivariate survival analyses were performed using 
the Cox proportional hazards regression model. A value of p<0.05 was considered 
statistically significant in all analyses.  
 
Results 
Immunohistochemistry for C4d. Representative results of immunohistochemistry for 
C4d are shown in Figure 1. In normal squamous epithelium of the esophagus, C4d 
staining was positive in the cytoplasm of the basal layer (Figure 1a). In ESCC, C4d 
staining in the cytoplasm varied among the tumor tissues. Several staining patterns 
were observed for C4d expression in the same tumor tissues. We evaluated C4d 
staining at the invasive front of the tumor tissue. We defined identical or weaker 
staining in ESCC than in normal squamous epithelium as negative C4d expression, 
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and stronger staining in ESCC than in normal squamous epithelium as positive C4d 
expression.  
 
Relationship between C4d expression and clinicopathological findings. The 
relationship between C4d expression and clinicopathological characteristics is shown 
in Table I. Positive C4d expression was observed in 70 (61.4%) cases and negative 
expression in 44 (38.6%). There was a significant inverse correlation between C4d 
expression and depth of tumor invasion (p=0.0001), lymph node metastasis 
(p=0.011), lymphatic invasion (p=0.033), and TNM stage (p=0.0021). There was a 
significant correlation between C4d expression and tumor location (p=0.001). 
However, there was no significant association with patient age, gender, or blood 
vessel invasion.  
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Relationship between C4d and survival. Kaplan–Meier analysis showed that 
negative C4d expression tended to lead to shorter overall survival (p=0.232) (Figure 
2a). No association was found between C4d staining and disease-free survival 
(Figure 2b). Multivariate analysis also showed no significant association. 
 
Discussion  
There are three complement activation pathways: classical, mannose-binding lectin, 
and alternative. The three complement pathways converge in the activation of C3, 
finally forming the membrane attack complex (MAC), which causes cell death (20). 
C4d is produced by the classical pathway, which is activated by C1qrs complex and 
derives from C4b, which has an internal thioester in the molecule. When C4d is 
cleaved from C4b, the covalent bond between C4d and the tissue membrane 
remains intact. Covalent-bound C4d has a longer half-life, and therefore remains at 
the site (21). According to this theory, the tissue membrane should be stained for 
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C4d. However, in our study, C4d staining was mainly in the cytoplasm and 
membrane.  
Covalent-bound C4d is used for immunological evaluation. For example, C4d 
is used as a marker for antibody-mediated rejection (AMR) of renal allografts. 
Diagnostic criteria for AMR of renal allografts have been established, and 
quantitative cutoff values for C4d added to the Banff criteria (22). C4d expression in 
peritubular capillaries is one of the diagnostic criteria of AMR. C4d expression 
reflects the function of the immune system that removes non-self tissue. Therefore, it 
is possible that the negative C4d expression in the current study reflected an 
aberrant immune response as a result of immune evasion.  
Our study showed that negative C4d expression was associated with 
progression of ESCC, advanced depth of tumor invasion, lymph node metastasis, 
lymphatic invasion, and TNM stage. C4d expression and tumor location were 
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significantly correlated. We hypothesize that advanced cancer may inactivate the 
immune system and suppress expression of C4d.  
Corrales et al. have suggested that complement-deficient mice have 
decreased tumor growth compared with wild-type mice (5, 23, 24). Ajona et al. 
reported positive C4d expression to be associated with progression of cancer, such 
as depth of tumor invasion, lymph node metastasis, and TNM stage, or prognosis of 
the disease in oropharyngeal or lung cancer (17, 18). From these reports, we 
suggest that complement activation promotes carcinogenesis. Hence we believe 
complement activation is related to the traditional hypothesis.   
 In contrast, our study showed the relationship between negative C4d 
expression and advanced cancer. This suggests that negative C4d expression 
induces immune response evasion, that is, immune tolerance. Immune tolerance 
might inhibit cell death induced by MAC. If cancer cell death is not induced, cancer 
cells continue to grow and carcinogenesis is promoted. MAC might contribute to the 
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increase in cancer cells in advanced ESCC, while MAC removes cancer cell in other 
tumor types. This might apply to the immunoediting theory in ESCC. 
Ajona et al. showed by computed tomography that plasma C4d levels in 
asymptomatic patients with lung cancer (histologically, 53.6% of patients had 
adenocarcinoma and 46.4% had SCC) were higher than in controls (18). The plasma 
C4d level may be a sensitive screening marker. Patients diagnosed with stage I lung 
cancer had lower plasma C4d levels than those diagnosed with stage II disease. 
Higher C4d expression evaluated by immunohistochemistry and a higher plasma 
C4d level resulted in significantly worse overall survival. These results suggest that 
plasma C4d levels may predict the risk of lung cancer in asymptomatic individuals 
and be of value in early diagnosis. In our study, patients with early-stage ESCC had 
higher levels of C4d expression than those with advanced-stage disease. 
Consequently, evaluation of C4d expression may be useful as a screening tool in 
ESCC. However, in advanced ESCC, the evaluation of C4d expression would not be 
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useful for screening because of decreased C4d expression. Ajona et al. examined 
immunohistochemistry as well as plasma C4d levels in patients with lung cancer 
(18). Therefore, the role of C4d in ESCC should be examined by other procedures. 
The expression of complement protein and induction of cancer initiation and 
progression by complement may differ in each type of tumor. 
Patients with upper thoracic ESCC have more superficial tumor invasion 
than patients with middle or lower thoracic ESCC. As a result, this suggests that 
there might be a significant relationship between C4d expression and tumor location. 
But, we considered that there are no relationship between C4d expression and tumor 
location. Our statistical analysis showed that there was no significant relationship 
between C4d expression and patient prognosis. Most of our patients had early-stage 
ESCC, which might have been a factor in this result. 
Finally, we indicated that C4d might be useful for early diagnosis in ESCC. If 
complement activation can be stopped at the stage where C4d is cleaved from C4b, 
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such as C1qrs complex, it might be possible to suppress the development of ESCC. 
A study on the relation between immune response and carcinogenesis of C4d may 
be useful in the early diagnosis, treatment planning, and suppression of ESCC. 
 In conclusion, the expression of C4d was lower in advanced than in early 
ESCC and normal squamous epithelium of the esophagus. Moreover, a lower 
expression of C4d tended to lead to shorter overall survival. Further research is 
needed to establish the role of C4d in ESCC, and for its use in early diagnosis and 
treatment of ESCC. 
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Table I. Relationship between C4d expression and clinicopathological characteristics 
in patients with esophageal squamous cell carcinoma. 
 
Figure 1. Representative results of immunohistochemistry for C4d. a: C4d 
expression in normal squamous epithelium of the esophagus. C4d staining was 
positive in the cytoplasm of the basal layer. b: Positive C4d expression was stronger 
in esophageal squamous cell carcinoma (ESCC) than normal squamous epithelium. 
c: Negative C4d expression was defined as identical or weaker staining in ESCC 
than in normal squamous epithelium. 
 
Figure 2. Relationship between C4d expression and postoperative overall (a) and 
disease-free (b) survival . The 5-year overall survival rate in patients with negative 
C4d expression was 61.0% and 68.6% in those with positive C4d expression. 
Negative C4d expression tended to lead to shorter overall survival than positive C4d 
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expression did. The 5-year disease-free survival rate in patients with negative C4d 
expression was 64.3% and 69.4% in those with positive C4d expression. No 
association was found between C4d staining intensity and disease-free survival.  
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